Mary Chebib

List of Publications by Year
in descending order

80 papers	2,876 citations	147726 31 h-index	189801 50 g-index
81 all docs	81 docs citations	81 times ranked	3719 citing authors

#	Article	IF	Citations
1	Gain-of-function variants in GABRD reveal a novel pathway for neurodevelopmental disorders and epilepsy. Brain, 2022, 145, 1299-1309.	3.7	34
2	Roles of hydrophilic residues in GABA binding site of GABA-Ï1 receptor explain the addition/inhibition effects of competitive ligands. Neurochemistry International, 2022, 153, 105258.	1.9	3
3	Pharmacological Effect of GABA Analogues on GABA-Ï±2 Receptors and Their Subtype Selectivity. Life, 2022, 12, 127.	1.1	2
4	Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies. Nature Communications, 2022, 13, 1822.	5.8	32
5	The de novo GABRA4 p.Thr300Ile variant found in a patient with earlyâ€onset intractable epilepsy and neurodevelopmental abnormalities displays gainâ€ofâ€function traits. Epilepsia, 2022, 63, 2439-2441.	2.6	6
6	The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations. Neuropharmacology, 2021, 182, 108371.	2.0	3
7	Efficient expression of concatenated Î±1Î²2Î´ and Î±1Î²3Î´ GABA_A receptors, their pharmacology and stoichiometry. British Journal of Pharmacology, 2021, 178, 1556-1573.	2.7	6
8	Targeting GABAC Receptors Improves Post-Stroke Motor Recovery. Brain Sciences, 2021, 11, 315.	1.1	8
9	Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. British Journal of Pharmacology, 2021, 178, 4826-4841.	2.7	32
10	Delta-containing GABAA receptors in pain management: Promising targets for novel analgesics. Neuropharmacology, 2021, 195, 108675.	2.0	10
11	Novel methyllycaconitine analogues selective for the Î±4Î²2 over Î±7 nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 2021, 51, 116516.	1.4	2
12	AE Succinimide, an Analogue of Methyllycaconitine, When Bound Generates a Nonconducting Conformation of the Î±4Î²2 Nicotinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2020, 11, 344-355.	1.7	3
13	Ligand-gated ion channels in genetic disorders and the question of efficacy. International Journal of Biochemistry and Cell Biology, 2020, 126, 105806.	1.2	3
14	The Z-Drugs Zolpidem, Zaleplon, and Eszopiclone Have Varying Actions on Human GABAA Receptors Containing Î³1, Î³2, and Î³3 Subunits. Frontiers in Neuroscience, 2020, 14, 599812.	1.4	19
15	Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies. Brain Communications, 2020, 2, fcaa162.	1.5	21
16	Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia, 2019, 60, 2224-2234.	2.6	103
17	Novel Approach for the Search for Chemical Scaffolds with Activity at Both Acetylcholinesterase and the Î±7 Nicotinic Acetylcholine Receptor: A Perspective on Scaffolds with Dual Activity for the Treatment of Neurodegenerative Disorders. Molecules, 2019, 24, 446.	1.7	13
18	Concatenated Î³-aminobutyric acid type A receptors revisited: Finding order in chaos. Journal of General Physiology, 2019, 151, 798-819.	0.9	12

#	Article	IF	Citations
19	GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators. European Journal of Medicinal Chemistry, 2019, 171, 434-461.	2.6	41
20	Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic. Journal of Biological Chemistry, 2019, 294, 6157-6171.	1.6	20
21	Revisiting autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) mutations in the nicotinic acetylcholine receptor reveal an increase in efficacy regardless of stochiometry. Pharmacological Research, 2019, 139, 215-227.	3.1	10
22	Optimising the transient expression of GABA(A) receptors in adherent HEK293 cells. Protein Expression and Purification, 2019, 154, 7-15.	0.6	0
23	The flavonoid, 2â€²-methoxy-6-methylflavone, affords neuroprotection following focal cerebral ischaemia. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1266-1282.	2.4	18
24	Galantamine is not a positive allosteric modulator of human Î±4Î²2 or Î±7 nicotinic acetylcholine receptors. British Journal of Pharmacology, 2018, 175, 2911-2925.	2.7	38
25	GABA_A receptors: Various stoichiometrics of subunit arrangement in Î±1Î²3 and Î±1Î²3Îµ receptors. Current Pharmaceutical Design, 2018, 24, 1839-1844.	0.9	7
26	The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors. Pharmacological Research, 2017, 119, 358-370.	3.1	164
27	GABAâ€•receptors: distinctive functions and molecular pharmacology. British Journal of Pharmacology, 2017, 174, 1881-1894.	2.7	39
28	GABA A Receptors and the Diversity in their Structure and Pharmacology. Advances in Pharmacology, 2017, 79, 1-34.	1.2	119
29	The Synthesis and Evaluation of Fluoroâ€, Trifluoromethylâ€, and Iodomuscimols as GABA Agonists. Chemistry - A European Journal, 2017, 23, 10848-10852.	1.7	7
30	Ligand Binding at the Î±4-Î±4 Agonist-Binding Site of the Î±4Î²2 nAChR Triggers Receptor Activation through a Pre-Activated Conformational State. PLoS ONE, 2016, 11, e0161154.	1.1	18
31	GABA-A Receptor Modulation and Anticonvulsant, Anxiolytic, and Antidepressant Activities of Constituents fromArtemisia indicaLinn. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-12.	0.5	32
32	Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism. PLoS ONE, 2016, 11, e0157700.	1.1	59
33	A pharmacological assessment of agonists and modulators at Î±4Î²2Î³2 and Î±4Î²2Î´ GABA A receptors: The challenge in comparing apples with oranges. Pharmacological Research, 2016, 111, 563-576.	3.1	35
34	A pharmacological characterization of GABA, THIP and DS2 at binary Î±4Î²3 and Î²3Î´ receptors: GABA activates Î²3Î´ receptors via the Î²3(+)Î´(â^') interface. Brain Research, 2016, 1644, 222-230.	1.1	17
35	Zolpidem is a potent stoichiometry-selective modulator of Î±1Î²3 GABAA receptors: evidence of a novel benzodiazepine site in the Î±1-Î±1 interface. Scientific Reports, 2016, 6, 28674.	1.6	34
36	High and low GABA sensitivity Î±4Î²2Î´ GABAA receptors are expressed in Xenopus laevis oocytes with divergent stoichiometries. Biochemical Pharmacology, 2016, 103, 98-108.	2.0	23

#	Article	IF	Citations
37	Investigating the Role of Loop C Hydrophilic Residue â€˜T244â€™ in the Binding Site of Ï1 GABAC Receptors via Site Mutation and Partial Agonism. PLoS ONE, 2016, 11, e0156618.	1.1	7
38	Pinnatoxins E, F and G target multiple nicotinic receptor subtypes. Journal of Neurochemistry, 2015, 135, 479-491.	2.1	15
39	Innate Immunity and Inflammation Post-Stroke: An Î±7-Nicotinic Agonist Perspective. International Journal of Molecular Sciences, 2015, 16, 29029-29046.	1.8	51
40	Antidepressant, Anxiolytic and Antinociceptive Activities of Constituents from Rosmarinus Officinalis. Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18, 448.	0.9	60
41	Interactions of Flavonoids with Ionotropic GABA Receptors. Advances in Pharmacology, 2015, 72, 189-200.	1.2	34
42	Oxytocin prevents ethanol actions at Î´ subunit-containing GABA _A receptors and attenuates ethanol-induced motor impairment in rats. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3104-3109.	3.3	70
43	GABAA receptor modulation and neuropharmacological activities of viscosine isolated from Dodonaea viscosa (Linn). Pharmacology Biochemistry and Behavior, 2015, 136, 64-72.	1.3	30
44	Engineered Î±4Î²2 nicotinic acetylcholine receptors as models for measuring agonist binding and effect at the orthosteric low-affinity Î±4â€“Î±4 interface. Neuropharmacology, 2015, 92, 135-145.	2.0	23
45	Comparison of templates for homology model of Ï1 GABA C receptors: More insights to the orthosteric binding siteâ€™s structure and functionality. Journal of Molecular Graphics and Modelling, 2015, 62, 43-55.	1.3	10
46	A Hydrophobic Area of the GABA Ï1 Receptor Containing Phenylalanine 124 Influences Both Receptor Activation and Deactivation. Journal of Molecular Neuroscience, 2015, 55, 305-313.	1.1	0
47	The Direct Actions of GABA, 2â€™-Methoxy-6-Methylflavone and General Anaesthetics at Î²3Î³2L GABAA Receptors: Evidence for Receptors with Different Subunit Stoichiometries. PLoS ONE, 2015, 10, e0141359.	1.1	14
48	Regional Fos-expression induced by Î³-hydroxybutyrate (GHB): Comparison with Î³-butyrolactone (GBL) and effects of co-administration of the GABAB antagonist SCH 50911 and putative GHB antagonist NCS-382. Neuroscience, 2014, 277, 700-715.	1.1	7
49	Modulation of Ionotropic GABA Receptors by 6-Methoxyflavanone and 6-Methoxyflavone. Neurochemical Research, 2014, 39, 1068-1078.	1.6	22
50	Presence of multiple binding sites on Î±9Î±10 nAChR receptors alludes to stoichiometric-dependent action of the Î±-conotoxin, Vc1.1. Biochemical Pharmacology, 2014, 89, 131-140.	2.0	34
51	GABAA Receptors Containing Ï1 Subunits Contribute to In Vivo Effects of Ethanol in Mice. PLoS ONE, 2014, 9, e85525.	1.1	50
52	Potency of GABA at human recombinant GABAA receptors expressed in Xenopus oocytes: a mini review. Amino Acids, 2013, 44, 1139-1149.	1.2	58
53	Design, Synthesis, and Pharmacological Evaluation of Fluorescent and Biotinylated Antagonists of Ï₁ GABA_C Receptors. ACS Medicinal Chemistry Letters, 2013, 4, 402-407.	1.3	22
54	Covalent Trapping of Methyllycaconitine at the Î±4-Î±4 Interface of the Î±4Î²2 Nicotinic Acetylcholine Receptor. Journal of Biological Chemistry, 2013, 288, 26521-26532.	1.6	17

#	Article	IF	Citations
55	Î±4Î²2Î´ GABA _A receptors are high-affinity targets for Î³-hydroxybutyric acid (GHB). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13404-13409.	3.3	87
56	The enantiomers of syn-2,3-difluoro-4-aminobutyric acid elicit opposite responses at the GABA_Creceptor. Chemical Communications, 2012, 48, 829-831.	2.2	51
57	Covalent attachment of antagonists to the Î±7 nicotinic acetylcholine receptor: synthesis and reactivity of substituted maleimides. Chemical Communications, 2012, 48, 6699.	2.2	12
58	2â€²â€Methoxyâ€6â€methylflavone: a novel anxiolytic and sedative with subtype selective activating and modulating actions at GABA_A receptors. British Journal of Pharmacology, 2012, 165, 880-896.	2.7	44
59	Low nanomolar GABA effects at extrasynaptic Î±4Î²1/Î²3Î´ GABAA receptor subtypes indicate a different binding mode for GABA at these receptors. Biochemical Pharmacology, 2012, 84, 549-557.	2.0	37
60	Novel Cyclic Phosphinic Acids as GABA_C Ï•Receptor Antagonists: Design, Synthesis, and Pharmacology. ACS Medicinal Chemistry Letters, 2011, 2, 11-16.	1.3	27
61	Flavonoid modulation of GABA_A receptors. British Journal of Pharmacology, 2011, 163, 234-245.	2.7	192
62	Naringin directly activates inwardly rectifying potassium channels at an overlapping binding site to tertiapinâ€Q. British Journal of Pharmacology, 2011, 163, 1017-1033.	2.7	49
63	3-Hydroxy-2â€²-methoxy-6-methylflavone: A potent anxiolytic with a unique selectivity profile at GABAA receptor subtypes. Biochemical Pharmacology, 2011, 82, 1971-1983.	2.0	37
64	Identifying the Binding Site of Novel Methyllycaconitine (MLA) Analogs at Î±4Î²2 Nicotinic Acetylcholine Receptors. ACS Chemical Neuroscience, 2010, 1, 796-809.	1.7	11
65	Novel, Potent, and Selective GABA_C Antagonists Inhibit Myopia Development and Facilitate Learning and Memory. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 448-457.	1.3	71
66	Alpha9 nicotinic acetylcholine receptors and the treatment of pain. Biochemical Pharmacology, 2009, 78, 693-702.	2.0	132
67	Guanidino Acids Act as Ï1 GABAC Receptor Antagonists. Neurochemical Research, 2009, 34, 1704-1711.	1.6	22
68	The Flavonoid Glycosides, Myricitrin, Gossypin and Naringin Exert Anxiolytic Action in Mice. Neurochemical Research, 2009, 34, 1867-1875.	1.6	94
69	Flavan-3-ol derivatives are positive modulators of GABAA receptors with higher efficacy for the Î±2 subtype and anxiolytic action in mice. Neuropharmacology, 2008, 55, 900-907.	2.0	49
70	(3-Aminocyclopentyl)methylphosphinic acids: Novel GABAC receptor antagonists. Neuropharmacology, 2007, 52, 779-787.	2.0	10
71	Modulation of Ionotropic GABA Receptors by Natural Products of Plant Origin. Advances in Pharmacology, 2006, 54, 285-316.	1.2	80
72	Methyllycaconitine analogues have mixed antagonist effects at nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 2005, 13, 4565-4575.	1.4	61

#	Article	IF	Citations
73	6-Methylflavanone, a more efficacious positive allosteric modulator of Î³-aminobutyric acid (GABA) action at human recombinant Î±2Î²2Î³2L than at Î±1Î²2Î³2L and Î±1Î²2 GABAA receptors expressed in Xenopus oocytes. European Journal of Pharmacology, 2005, 512, 97-104.	2.7	36
74	Flumazenil-independent positive modulation of Î³-aminobutyric acid action by 6-methylflavone at human recombinant Î±1Î²2Î³2L and Î±1Î²2 GABAA receptors. European Journal of Pharmacology, 2004, 491, 1-8.	1.7	40
75	The dietary flavonoids apigenin and (â^')-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABAA receptors. Biochemical Pharmacology, 2004, 68, 1631-1638.	2.0	129
76	Stabilization of Zwitterions in Solution:â€‰ Î³-Aminobutyric Acid (GABA). Journal of Physical Chemistry A, 2004, 108, 203-211.	1.1	42
77	Role of AÎ² and the Î±7 nicotinic acetylcholine receptor in regulating synaptic plasticity in Alzheimer's disease. International Journal of Peptide Research and Therapeutics, 2003, 10, 401-404.	0.1	1
78	Convulsant actions of calycanthine. Toxicology and Applied Pharmacology, 2003, 190, 58-64.	1.3	19
79	Role of A Î² and the Î± 7 nicotinic acetylcholine receptor in regulating synaptic plasticity in Alzheimer's disease. International Journal of Peptide Research and Therapeutics, 2003, 10, 401-404.	0.9	0
80	An improved, versatile synthesis of the GABAC antagonists (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA) and (piperidin-4-yl)methylphosphinic acid (P4MPA). Journal of the Chemical Society, Perkin Transactions 1, 2001, , 2389-2392.	1.3	25